Patient-derived CML cells and LSCs in mouse models of CML express programmed death ligand-1 (PD-L1), the blockade of which triggers the loss of LSCs and prevents development of CML-like disease, if combined with T-cell immunotherapy [22,27]. The gene discussed is CD274; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.